Compare DMRA & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMRA | PRCT |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2020 | 2021 |
| Metric | DMRA | PRCT |
|---|---|---|
| Price | $24.85 | $24.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $46.00 | $35.44 |
| AVG Volume (30 Days) | 217.1K | ★ 1.2M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $31.34 |
| Revenue Next Year | N/A | $24.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $16.50 | $19.35 |
| 52 Week High | $28.76 | $64.89 |
| Indicator | DMRA | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 45.32 |
| Support Level | $23.65 | $22.81 |
| Resistance Level | $28.00 | $26.55 |
| Average True Range (ATR) | 2.13 | 1.14 |
| MACD | -0.14 | 0.10 |
| Stochastic Oscillator | 28.16 | 42.19 |
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.